Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.41 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.38 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.34 |
| ▸ | BRD4 | O60885 | 9/20 | 0.34 |
| ▸ | EP300 | Q09472 | 4/20 | 0.34 |
| ▸ | PGR | P06401 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1542310 | 0.76 | CYP3A4 (0.47) | CYP3A4EPHX2PDPK1BRD4EP300 | |
| SCHEMBL1542584 | 0.75 | CYP3A4 (0.62) | CYP3A4EPHX2PDPK1BRD4EP300 | |
| SCHEMBL2127415 | 0.75 | CYP3A4 (0.62) | CYP3A4EPHX2PDPK1BRD4EP300 | |
| SCHEMBL1542324 | 0.75 | CYP3A4 (0.62) | CYP3A4EPHX2EP300 | |
| SCHEMBL3765201 | 0.74 | ALOX5AP (0.45) | CYP3A4 | |
| SCHEMBL2128063 | 0.73 | CYP3A4 (0.47) | CYP3A4EPHX2PDPK1BRD4EP300 | |
| SCHEMBL2128070 | 0.73 | CYP3A4 (0.47) | CYP3A4EPHX2PDPK1BRD4EP300 | |
| SCHEMBL2128068 | 0.73 | CYP3A4 (0.47) | CYP3A4EPHX2PDPK1BRD4EP300 | |
| SCHEMBL726323 | 0.73 | CYP3A4 (0.64) | CYP3A4EPHX2PDPK1BRD4EP300 | |
| SCHEMBL2127134 | 0.72 | CYP3A4 (0.48) | CYP3A4PDPK1BRD4EP300 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | claimed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | claimed |
| EP-2307372-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | claimed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | claimed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | claimed |
| US-8273773-B2 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC (US) | 2012-09-25 | — | — | US | disclosed |
| EP-2307372-B1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2012-04-25 | — | — | EP | disclosed |
| EP-2307372-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. Hoffmann-La Roche AG (CH) | 2011-04-13 | — | — | EP | disclosed |
| WO-2010010017-A1 | HETEROCYCLIC ANTIVIRAL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-01-28 | — | — | WO | disclosed |
| US-20100021423-A1 | Heterocyclic antiviral compounds | ROCHE PALO ALTO LLC | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100021423-A1 | Heterocyclic antiviral compounds | POLR2A, RRM2B, RRP1B | CYP3A4 528/4885EPHX2 3098/4885PDPK1 4145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.